source
- Vanda halts Novartis-originated social anxiety drug after Phase 3 missVanda Pharmaceuticals announced it is suspending development of VQW-765, a social anxiety disorder candidate licensed from Novartis, after the drug failed to demonstrate a statistically significant…
- FDA issues warning letters to manufacturers over CGMP and GLP violationsThe U.S. Food and Drug Administration has sent warning letters to multiple drug manufacturers for failing to meet current good manufacturing practice requirements. The agency highlighted problems e…